Alumis Inc. · NASDAQ:ALMS
Alumis — Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast (January 2026)
25 slides from Alumis's conference presentation, Jan 6, 2026
Slide 1: Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout
Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast – January 6, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of
Slide 3: Agenda
Agenda Topic Speaker Welcome John Schroer, CFO Opening Remarks Martin Babler, CEO ONWARD Phase 3 Data Review Jörn Drappa, MD, PhD, CMO Psoriasis Opportunity Martin Babler, CEO Q&A All 3
Slide 4: Overview
alumis Overview alumis
Slide 5: ONWARD1 and ONWARD2 Met All Primary and Secondary Endpoints
ONWARD1 and ONWARD2 Met All Primary and Secondary Endpoints • Leading skin clearance for oral plaque Highly statistically Rapid onset of psoriasis therapies significant Phase 3 action, with clear efficacy with deep separation from • We believe envudeucitinib profile is skin clearance placebo for PAS
Slide 6: Alumis' Next-Gen TYK2 Inhibitors: Two Pipelines-in-a-Pill
Alumis' Next-Gen TYK2 Inhibitors: Two Pipelines-in-a-Pill Highly statistically significant Phase 3 efficacy, rapid onset, deep skin clearance at Week 24 Positive Leading skin clearance among oral plaque psoriasis therapies Psoriasis Phase 3 Favorable safety and tolerability profile consistent with P
Slide 7: Positioned to Unlock the Full Potential of TYK2i Mechanism
Positioned to Unlock the Full Potential of TYK2i Mechanism Hypothesis demonstrated: maximal target engagement translates into higher clinical efficacy Power of TYK2i Human Genetics: TYK2 loss-of-function variants protect against immune mediated disorders Known Mechanism: TYK2 is an upstream mediator
Slide 8: 2026 is Expected to be a Breakout Year for Envudeucitinib
2026 is Expected to be a Breakout Year for Envudeucitinib Precision engineered oral TYK2i with differentiated profile Psoriasis: Potential best-in-disease oral (Ph3 data) SLE: Potential oral category leader Confirmed TYK2 viability as oral IL-23/IL-17 pathway inhibitor Evaluating TYK2 viability as T
Slide 9: Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Data
Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Data 9
Slide 10: Phase 3 Psoriasis Clinical Program: Well-Designed and Rapidly Executed
Phase 3 Psoriasis Clinical Program: Well-Designed and Rapidly Executed Two Phase 3 trials and LTE to evaluate efficacy & safety of envudeucitinib in moderate-to-severe plaque psoriasis Treatment Period Maintenance LTE Open Label Envudeucitinib, 40mg BID (N=420) Wk 16: Rollover to envudeucitinib R Pl
Slide 11: All Primary and Secondary Endpoints Met with High Statistical Significance
All Primary and Secondary Endpoints Met with High Statistical Significance ONWARD1 and ONWARD2 topline data Week 16 Envudeucitinib Week 24 Envudeucitinib Primary Endpoints 40 mg BID Secondary Endpoints 40 mg BID PASI 75 74% PASI 90 65% sPGA 0/1 59% PASI 100 >40% • Both trials met all primary and sec
Slide 12: Envudeucitinib Delivered a Favorable Safety Profile
Envudeucitinib Delivered a Favorable Safety Profile ONWARD1 and ONWARD2 topline data Envudeucitinib Topline Safety Summary • Generally well tolerated through Week 24 in both ONWARD1 and ONWARD2 and consistent with Alumis’ Phase 2 program, including the Phase 2 open-label extension • No new safety si
Slide 13: ONWARD: a Global Phase 3 Development Program
ONWARD: a Global Phase 3 Development Program 1700+ patients enrolled at >270 study sites in 10 months (ESK-001-016) Australia Bulgaria Belgium Canada Czech Republic Germany Japan Portugal Poland South Korea United States (ESK-001-017) Austria Canada Estonia France Germany Hungary Latvia Poland Puert
Slide 14: ONWARD1 and ONWARD2: Key Inclusion and Exclusion Criteria
ONWARD1 and ONWARD2: Key Inclusion and Exclusion Criteria Entry criteria reflects a moderate-to-severe plaque psoriasis adult population Key inclusion criteria Key exclusion criteria • Males or females, age ≥18 years at the Screening Visit • Non-plaque psoriasis (e.g., guttate, inverse, pustular, e
Slide 15: Demographics and Baseline Characteristics for ONWARD1 and ONWARD2
Demographics and Baseline Characteristics for ONWARD1 and ONWARD2 Balanced patients and disease characteristics across groups Demographics similar between both trials Baseline disease characteristics similar between both trials • 64-67% Male • Over 40% prior systemic use • 79-89% White • Approximate
Slide 16: We Expect to Share Additional Data at Future Medical Conferences
We Expect to Share Additional Data at Future Medical Conferences ONWARD1 & • PASI 75 vs. placebo at week 16 ONWARD2 Primary Endpoints • sPGA 0/1 vs. placebo at week 16 Efficacy Patient Reported Outcomes Special Area Involvement ONWARD1 & • PASI 75 at week 24 • PSSD at week 24 • Scalp ONWARD2 Seconda
Slide 17: Key Competitor Efficacy Comparison
Key Competitor Efficacy Comparison Envudeucitinib PASI 75, 90 and 100 response rates similar to or greater than icotrokinra PASI rates PASI 75 PASI 90 PASI 100 Week 16 Week 24 Week 24 74% 65% >40% Envudeucitinib Ico ADVANCE 1 Ico ADVANCE 2 Sotyktu Envudeucitinib data are presented as an average acro
Slide 18: Envudeucitinib Substantial Market Potential in Psoriasis
Envudeucitinib Substantial Market Potential in Psoriasis 18
Slide 19: Significant Disease Burden Remains in Psoriasis
Significant Disease Burden Remains in Psoriasis Many patients remain untreated or undertreated, despite available treatments Significant Unmet Market Opportunity Driven by Persistent Disease, Majority of Psoriasis Patients Remain Undertreatment, and High Therapy Discontinuation Untreated or Undertre
Slide 20: Multiple Entry Points Available in Growing Psoriasis Market
Multiple Entry Points Available in Growing Psoriasis Market High-efficacy orals well-positioned to capture market share in $40B projected market by 2030 1 Estimated Market Share Multiple Market Dynamics Drive Opportunity for Oral and by Brand and MOA2 Differentiated Therapies • No single Brand or Me
Slide 21: Key Drivers of Use in Psoriasis Treatment
Key Drivers of Use in Psoriasis Treatment HCP Treatment Goals: HCP Preferences Simplicity We are definitely lacking orals Easy regimens, minimal monitoring, and because whatever we have here 1 PASI 90/PASI 100 outcomes reduced administrative steps in terms of the orals, the efficacy 2 Low AEs Treati
Slide 22: Envudeucitinib Profile is Highly Compelling to Physicians and Patients
Envudeucitinib Profile is Highly Compelling to Physicians and Patients Market Need Envudeucitinib • Leading skin clearance responses for next generation oral therapies High Efficacy • Rapid onset of action: Clear separation from placebo as early as Week 4 for PASI 90 • Improvements across burdensome
Slide 23: Two Pipeline-in-a-Pill Opportunities; $180B+ Potential Total Market Opportunity
Two Pipeline-in-a-Pill Opportunities; $180B+ Potential Total Market Opportunity Indications supported by genomic evidence, clinical validation, or active studies Dermatology: $49B Plaque Psoriasis Vitiligo Hidradenitis Suppurativa Cutaneous Lupus Erythematosus Dermatomyositis Rheumatology: $38B
Slide 24: Late-stage Pipeline with Multiple Near-term Anticipated Milestones
Late-stage Pipeline with Multiple Near-term Anticipated Milestones Our pathway to patients Program Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones TYK2i 1H’26: Phase 3 data presentation Plaque Psoriasis 2H’26: NDA filing 2H’26: Phase 2 two-year data Envudeucitinib Systemic Lupu
Slide 25: Thank You!
alumis Thank You! alumis